Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.

Yucai Wang,Jonathan M. Loree,Cecilia Yu,Marcella Tschautscher,Andrew M. Briggler,Michael J. Overman,Russell Broaddus,Funda Meric-Bernstam,Jeremy Clifton Jones,Jessica R. Balcom,Benjamin R. Kipp,Scott Kopetz,Axel F Grothey

Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.

2018

Yucai Wang
Jonathan M. Loree
Cecilia Yu
Marcella Tschautscher
Andrew M. Briggler
Michael J. Overman
Russell Broaddus
Funda Meric-Bernstam
Jeremy Clifton Jones
Jessica R. Balcom
Benjamin R. Kipp
Scott Kopetz
Axel F Grothey

3513Background: RAS and BRAF mutations are associated with lack of response to anti-EGFR therapy and worse survival in patients with metastatic colorectal cancer (mCRC). NRAS mutations are less fre...

Keywords:

Neuroblastoma RAS viral oncogene homolog
KRAS
Pathology
Colorectal cancer
Medicine
in patient
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations